Despite considerable therapeutic advances for ER-positive and Her2-positive breast cancers, targeted drugs are not yet clinically available for TNBC [2] and their future development will require a better understanding of the biology of TNBC tumors. This evidence concerns the gene ESR1 and breast carcinoma.